Multinational pharmaceutical companies are being squeezed out of the Chinese drug market as a government bulk-buying scheme favors cheaper, local products. The process is gradual, but inventories of brand-name medicines sold by the likes of Roche, Pfizer and AstraZeneca are slowly dwindling as China adds more generic versions to its procurement list and encourages doctors to prescribe them.
In Depth: Brand-Name Drugs Feel the Squeeze in China’s Generic-Heavy Market
2023年06月02日 17:52
Multinational pharmaceutical firms are changing strategies and selling business lines, as a government bulk-buying program favors cheaper, local products
![]()
- All generic drugs considered for China's bulk-buying scheme must have already passed the country’s equivalency test for quality and efficacy. Photo: VCG
[财新双语通产品，是为有双语需求读者专门订制的优惠产品， 按此可享超值优惠订阅。]
版面编辑：喻竹杨洋
图片推荐
编辑推荐
最新文章
- 09:42人事观察｜历任两省份纪委书记 56岁刘爽转岗退役军人事务部
- 09:10大西洋观察｜尾大不掉的英国福利开支
- 08:38白宫新任发言人上任一周遭解雇 特朗普劝其重新考虑职业
- 08:21火车新增“X”字头 “K”、“T”字头从“绿皮车”变高铁
- 07:49世卫首份儿童青少年肥胖管理指南：倡导综合干预
- 07:46新能源投资格局重塑 资产金融化属性有望增强
- 22:072027年税务系统国考招录占比升至67%高位 原因何在？
- 22:02三季度全球手机出货量继续两位数下降 成本高企传导终端涨价
- 21:17禁止出口目录拟增列部分生物医药技术，涉及CGT、小核酸等
- 21:14美联储主席对话IMF总裁：AI对经济影响复杂，央行如何应对尾部风险
京公网安备 11010502034662号 
